IQWiG has announced that it has commenced its assessment of the following medicines:

• Aflibercept (Eylea) - new indication
• Idelalisib (Zydelig) - new medicine
• Albiglutide (Eperzan) - new medicine
• Sucroferric oxyhydroxide (Velphoro) - new formulation